These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 23545855)

  • 1. Imetelstat (a telomerase antagonist) exerts off‑target effects on the cytoskeleton.
    Mender I; Senturk S; Ozgunes N; Akcali KC; Kletsas D; Gryaznov S; Can A; Shay JW; Dikmen ZG
    Int J Oncol; 2013 May; 42(5):1709-15. PubMed ID: 23545855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiadhesive effects of GRN163L--an oligonucleotide N3'->P5' thio-phosphoramidate targeting telomerase.
    Jackson SR; Zhu CH; Paulson V; Watkins L; Dikmen ZG; Gryaznov SM; Wright WE; Shay JW
    Cancer Res; 2007 Feb; 67(3):1121-9. PubMed ID: 17283146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner.
    Frink RE; Peyton M; Schiller JH; Gazdar AF; Shay JW; Minna JD
    Oncotarget; 2016 May; 7(22):31639-51. PubMed ID: 27192120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor.
    Dikmen ZG; Gellert GC; Jackson S; Gryaznov S; Tressler R; Dogan P; Wright WE; Shay JW
    Cancer Res; 2005 Sep; 65(17):7866-73. PubMed ID: 16140956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oligonucleotide N3'-->P5' phosphoramidates as efficient telomerase inhibitors.
    Herbert BS; Pongracz K; Shay JW; Gryaznov SM
    Oncogene; 2002 Jan; 21(4):638-42. PubMed ID: 11850790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telomerase inhibitor Imetelstat (GRN163L) limits the lifespan of human pancreatic cancer cells.
    Burchett KM; Yan Y; Ouellette MM
    PLoS One; 2014; 9(1):e85155. PubMed ID: 24409321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oligonucleotide conjugate GRN163L targeting human telomerase as potential anticancer and antimetastatic agent.
    Gryaznov SM; Jackson S; Dikmen G; Harley C; Herbert BS; Wright WE; Shay JW
    Nucleosides Nucleotides Nucleic Acids; 2007; 26(10-12):1577-9. PubMed ID: 18066830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid modification of GRN163, an N3'-->P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition.
    Herbert BS; Gellert GC; Hochreiter A; Pongracz K; Wright WE; Zielinska D; Chin AC; Harley CB; Shay JW; Gryaznov SM
    Oncogene; 2005 Aug; 24(33):5262-8. PubMed ID: 15940257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of telomerase inhibition on preclinical models of malignant rhabdoid tumor.
    Hu Y; Bobb D; Lu Y; He J; Dome JS
    Cancer Genet; 2014 Sep; 207(9):403-11. PubMed ID: 25441685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telomerase targeted oligonucleotide thio-phosphoramidates in T24-luc bladder cancer cells.
    Dikmen ZG; Wright WE; Shay JW; Gryaznov SM
    J Cell Biochem; 2008 May; 104(2):444-52. PubMed ID: 18044713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines.
    Joseph I; Tressler R; Bassett E; Harley C; Buseman CM; Pattamatta P; Wright WE; Shay JW; Go NF
    Cancer Res; 2010 Nov; 70(22):9494-504. PubMed ID: 21062983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of
    Carloni LE; Wechselberger R; De Vijlder T
    Nucleic Acid Ther; 2021 Oct; 31(5):341-350. PubMed ID: 34018844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma.
    Djojosubroto MW; Chin AC; Go N; Schaetzlein S; Manns MP; Gryaznov S; Harley CB; Rudolph KL
    Hepatology; 2005 Nov; 42(5):1127-36. PubMed ID: 16114043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells.
    Koziel JE; Herbert BS
    Breast Cancer Res Treat; 2015 Feb; 149(3):607-18. PubMed ID: 25627551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oligonucleotide n3'-->p5' phosphoramidates and thio-phoshoramidates as potential therapeutic agents.
    Gryaznov SM
    Chem Biodivers; 2010 Mar; 7(3):477-93. PubMed ID: 20232321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer.
    Chiappori AA; Kolevska T; Spigel DR; Hager S; Rarick M; Gadgeel S; Blais N; Von Pawel J; Hart L; Reck M; Bassett E; Burington B; Schiller JH
    Ann Oncol; 2015 Feb; 26(2):354-62. PubMed ID: 25467017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer.
    Gellert GC; Dikmen ZG; Wright WE; Gryaznov S; Shay JW
    Breast Cancer Res Treat; 2006 Mar; 96(1):73-81. PubMed ID: 16319992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oligonucleotide N3' --> P5' thio-phosphoramidate telomerase template antagonists as potential anticancer agents.
    Gryaznov S; Asai A; Oshima Y; Yamamoto Y; Pongracz K; Pruzan R; Wunder E; Piatyszek M; Li S; Chin A; Harley C; Akinaga S; Yamashita Y
    Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):577-81. PubMed ID: 14565232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo.
    Shammas MA; Koley H; Bertheau RC; Neri P; Fulciniti M; Tassone P; Blotta S; Protopopov A; Mitsiades C; Batchu RB; Anderson KC; Chin A; Gryaznov S; Munshi NC
    Leukemia; 2008 Jul; 22(7):1410-8. PubMed ID: 18449204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer.
    Hochreiter AE; Xiao H; Goldblatt EM; Gryaznov SM; Miller KD; Badve S; Sledge GW; Herbert BS
    Clin Cancer Res; 2006 May; 12(10):3184-92. PubMed ID: 16707619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.